What the New Executive Order on Psychedelics Means — and What It Doesn't
What the New Executive Order on Psychedelics Means — and What It Doesn't
A note from Canto Integrative Psychiatry on the April 18, 2026 federal action and what it changes for patients seeking ketamine-assisted psychotherapy and other psychedelic-supported care.
On April 18, 2026, President Trump signed an executive order titled Accelerating Medical Treatments for Serious Mental Illness. It directs federal agencies (like the the FDA, DEA, HHS, and VA) to move more quickly on research, review, and access pathways for psychedelic medicines like psilocybin, MDMA, LSD, and ibogaine. It also allocates at least $50 million in federal funds to partner with state programs studying these compounds.
If you've been following the slow, careful work happening in psychedelic medicine for the past decade, this is a meaningful moment. It's also a moment that calls for nuance. So I want to walk you through what actually changed, what didn't, and what it means for the work we do here at Canto.
What the order actually does
In plain terms, the executive order does four main things:
It tells the FDA to fast-track certain psychedelic drugs. Specifically, drugs that have already received "Breakthrough Therapy" designation (a status the FDA gives to medicines that show early promise for serious conditions) can now be considered for "National Priority Vouchers". This is a pilot program aimed at compressing review times to roughly one to two months. Within six days of the order, the FDA had already issued three such vouchers, including two for psilocybin programs and one for a PTSD treatment.
It opens a "Right to Try" pathway for some patients. The federal Right to Try Act allows people with serious or life-threatening conditions to access experimental drugs that haven't yet been fully approved. The order directs the FDA and DEA to build a pathway for psychedelic medicines, including ibogaine, to be available under this law.
It funds federal-state collaboration. The $50 million is meant to support states that have already started (or are developing) their own psychedelic therapy programs. Oregon, Colorado, and a handful of others have been quietly building infrastructure for years.
It directs faster rescheduling. If a psychedelic drug successfully completes Phase 3 trials and gets approved by the FDA, the order asks the Attorney General to move quickly on rescheduling it out of Schedule I (the most restrictive DEA/controlled substance category).
What the order does not do
Here is where I want to be especially clear, because some of the headlines have been misleading.
Nothing is suddenly legal. Psilocybin, MDMA, LSD, and ibogaine remain federally controlled. An executive order is not FDA approval. It doesn't mean these medications are now available in routine psychiatric care, and it doesn't settle the open scientific questions about safety, effectiveness, or who is an appropriate candidate.
It doesn't address the therapy part of psychedelic-assisted therapy. The federal government has historically focused on the drug itself (things like its safety profile, its dose, its side effects) and treated the psychotherapy that wraps around the medicine as an afterthought. Scholars at Harvard's Petrie-Flom Center have noted that this order continues that pattern. But for those of us doing this work clinically, the preparation, the set and setting, the integration sessions afterward…these aren't optional add-ons. They are the treatment.
It doesn't resolve real safety concerns. The order's emphasis on ibogaine in particular has drawn careful pushback from researchers. Ibogaine carries documented cardiac risks, and most of its clinical research has happened outside the U.S. The Multidisciplinary Association for Psychedelic Studies (MAPS), which has been working on researching psychedelics like ibogaine for forty years, welcomed the order, but its leaders also urged that any acceleration must be paired with rigorous science, ethical frameworks, sustainability of the iboga plant itself, and respect for the Indigenous communities who have stewarded this medicine for generations.
Why this matters for the work we do at Canto
At Canto Integrative Psychiatry, ketamine-assisted psychotherapy is the psychedelic-supported treatment we currently offer. Ketamine occupies a unique position: it is a legal, FDA-approved medication that can be prescribed off-label, and it has profound psychedelic and dissociative properties when used in a therapeutic frame. So this executive order doesn't directly change what we're allowed to do tomorrow.
But it does something quieter and arguably more important: it signals that the federal posture toward psychedelic medicine is shifting from suspicion to serious engagement. That matters for several reasons.
It validates a model of care that pairs medicine with relationship. The order's gaps around psychotherapy are real, but the broader cultural conversation it advances is important. Some of the most stuck forms of suffering, including treatment-resistant depression and PTSD, may need approaches beyond standard prescriptions. This is exactly the conversation that brought many of our patients to Canto in the first place.
It acknowledges that veterans, survivors of trauma, and people living with addiction deserve more than what current first-line treatments can offer. As MAPS Co-Executive Director Betty Aldworth pointed out, people in desperate need of healing have been traveling abroad or self-medicating with unregulated substances. A regulated, supervised, integrated path forward is overdue, and necessary for public safety.
It points toward a future where MDMA, psilocybin, and other compounds may eventually become available within carefully designed clinical settings. These settings look a lot like what we have already built here. Our group studio space, our home-visit protocols, our preparation and integration models, our commitment to safety screening, informed consent, and cross-collaboration are all are the kinds of structures the field will need.
A measured optimism
I want to leave you with the same posture I bring to my clinical work: cautious, hopeful, grounded.
The opportunity is real. So is the responsibility. Psychedelic medicine is not a panacea, and the people who have spent careers in this work… the clinicians, researchers, Indigenous practitioners have always known that. The question now is whether the acceleration this order calls for will be matched by the rigor, the ethics, the training, and the support structures that make these medicines actually safe and actually healing.
That is what I’m working toward at Canto, every day, with every patient.
If this resonates with you
If you have been wondering whether ketamine-assisted psychotherapy might be a fit for you, for conditions like treatment-resistant depression, PTSD, anxiety, or simply the kind of suffering that hasn't responded to what you've already tried, I'd welcome a conversation. We offer thorough screening, careful preparation, and integrative support before, during, and after each session.
You can reach out through our website or call the practice directly. Whether or not we end up working together, I'm happy to help you think through whether this kind of care is right for where you are.
With care,
Sarah S. Tatko, DMSc, PA-C Canto Integrative Psychiatry Chapel Hill, NC
Sources and further reading:
The White House. "Accelerating Medical Treatments for Serious Mental Illness." Executive Order, April 18, 2026.
MAPS. "MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy." April 18, 2026.
Petrie-Flom Center, Harvard Law School. "A New Executive Order on Psychedelics: Q&A with I. Glenn Cohen and Mason Marks." April 2026.
TIME. "What to Know About Trump's New Executive Order on Psychedelic Drugs." April 21, 2026.
Psychology Today. "What the New Executive Order Means for Psychedelics." April 2026.
